SUMMARY Twenty patients with active systemic lupus erythematosus (SLE) were treated with methyl prednisolone pulse therapy (MPPT) and followed up for up to 24 weeks (mean 18 weeks). Beneficial effects of MPPT were observed principally on arthralgia, pleuritic pain, vasculitic skin rash, pyrexia, and lymphadenopathy. The serological tests showing the most improvement were ds DNA binding and the serum C3 level. MPPT was found to be both safe and easy to administer. It may be of value in treating patients with SLE whose disease is not controlled by moderate doses of corticosteroids and may also enable the dose of maintenance corticosteroids to be reduced appreciably.
A number of studies have been described in which lupus nephritis has been treated with methyl prednisolone pulse therapy (MPPT).'-3 The apparent success of this method has prompted an assessment of this form of treatment in a much wider variety of lupus manifestations. Where MPPT has been used before in nonrenal lupus most of the patients treated were severely ill.4 5 In this study patients with active disease were selected but not those in acute crisis or terminally ill. Thus it was hoped to establish whether MPPT might have a role in the routine management of active SLE by inducing clinical or serological improvement and in enabling the oral maintenance dose of corticosteroids to be reduced.
Patients, materials, and methods
Twenty patients, all female, with 4 or more of the American Rheumatism Association's criteria for the classification of systemic lupus erythematosus (SLE) were studied'(a positive antinuclear factor, 1>40, was however substituted for a positive LE cell test). Patients were stabilised so far as possible with regard to treatment during the 6 weeks prior to MPPT so that they could be used as their own controls in the subsequent assessments. Fifteen of the 20 patients were on regular maintenance oral prednisolone before MPPT, the others, all with active disease not controlled by nonsteroidal agents, would otherwise have started on oral corticosteroids. Five of the patients on oral prednisolone were also being treated with azathioprine.
MPPT comprised 1 g methyl prednisolone, given intravenously in 500 ml normal saline over 4 hours on 3 successive days. Arthralgia, pleuritic pain, and pyrexia were found to be the features most likely to respond.
The changes in laboratory tests and visual analogue scale, which applied to the whole group, are analysed in Table 3 . Changes in DNA binding and serum C3 level showed the most change. As indicated by the visual analogue results, the majority of patients felt better or showed no adverse response to the treatment (note: decrease in the scale means patients feel better).
Patients were subdivided into those with arthralgia, thrombocytopenia, and marked renal involvement (proteinuria >1 g/24 hours, +/-increased serum creatinine). The results of the changes in relevant tests for each subgroup are shown in Table 4 .
Patients were also divided into those on and off corticosteroid therapy immediately prior to MPPT. Fig. 1 shows the outcome, as judged by the alteration in daily oral prednisolone requirement. In 2 patients it proved possible to stop oral prednisolone and in 5 T -2 -migraine headaches within 24 hours of the last infusion. Two patients developed mild indigestion, and as a precaution the majority were given concomitant cimetidine (1 g per day for 1 week, beginning on the first day of MPPT). Three patients on oral prednisolone were given repeat courses of MPPT a minimum of 3 months after initial treatment which had had no effect. In two cases azathioprine was added to their therapy prior to the second course. Interestingly, 2 of these repeat courses were followed by clinical improvement. Insufficient data were available to judge the outcome of the 2 other patients given repeat MPPT (one on oral prednisolone, one not).
Of the 3 patients who deteriorated following MPPT one developed marked abdominal serositis 6 weeks after treatment, one developed marked thrombocytopenia and hypertension 7 weeks after treatment, and one with mild cerebral involvement became grossly psychotic within 2 weeks of MPPT. Fig. 2 shows the response of a 46-year-old patient with arthralgia, vasculitic skin rash, and serological abnormalities typical of SLE.
Discussion
MPPT has previously been used in the treatment of lupus nephritis,`' nonrenal lupus,45 rapidly progressive glomerulonephritis,7-9 minimal change nephrotic syndrome,"0 rheumatoid arthritis," 12 multiple 
